Clinical Trial Update: Denosumab as an add-on Neoadjuvant Treatment (GeparX) [Phase 2]

View source ↗

Summary

Phase 2 trial update on denosumab added to neoadjuvant therapy for various breast cancer subtypes; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Inflammatory Breast Cancer
• Invasive Ductal Breast Cancer
• Mucinous Breast Cancer
• Tubular Breast Cancer

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Breast Cancer Female NOS, Tubular Breast Cancer Stage II | Phase 2 | Status: COMPLETED